This work demonstrates that radiopharmaceuticals [18F]FB-Gol1 and [18F]FB-GR20 bind to rat 101.8 glioblastoma and can serve as promising drug candidates for the selective diagnosis of EGFR expression in glial tumors. This evidence concerns the gene EGFR and glioblastoma.